European Psychiatry (Apr 2021)

The role of Vit D and parathyroid hormone in clinical severity of patients with bipolar disorder

  • C. Palummo,
  • L. Marone,
  • V. Caivano,
  • A. Vece,
  • L. Steardo,
  • M. Luciano,
  • A. Di Cerbo,
  • V. Del Vecchio,
  • A. Fiorillo

DOI
https://doi.org/10.1192/j.eurpsy.2021.243
Journal volume & issue
Vol. 64
pp. S81 – S81

Abstract

Read online

Introduction Vitamin D modulates the biosynthesis of neurotransmitters and neurotrophic factors, thus influencing mood and its alterations. Decreased blood levels of Vitamin D are involved in many psychiatric disorders, in particular, affective disorders. As regards bipolar disorder (BD), an association between vitamin D deficiency and severity of illness has been found. Objectives In this observational study, we assessed calcium homeostasis imbalance in a sample of patients with BD; in particular, we explored whether serum levels of PTH, Vitamin D and calcium influence the clinical presentation of BD and its symptom severity. Methods All patients were administered with validated assessment instruments to assess psychopathology, affective temperaments and global functioning. Vitamin D and PTH levels were assessed in all patients. An-ad hoc schedule was administered for socio-demographic and clinical characteristics. Results The total sample consisted of 199 patients (females: 51%; mean age: 47.1 ± 13.2 years). Levels of serum PTH were directly correlated with the total number of hospitalizations (p< 0.01), and of depressive (p< 0.0001), manic (p< 0.001) and hypomanic episodes (p< 0.01). Serum levels of Vitamin D were positively associated with age at first psychiatric contact and were inversely correlated with the total number of depressive episodes (p< 0.05) and cyclothymic temperament (p< 0.05). Conclusions Increased levels of PTH and Vit D correlate with a worse clinical outcome of patients with BD. Our results highlight the importance to routinely assess PTH, Vit D and calcium levels in BD patients. Moreover, vitamin D may represent a valid add-on treatment for these patients. Disclosure No significant relationships.

Keywords